

## Disclosures

### Personal Commercial (33)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Ambry Genetics	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amicus	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Audentes	Data Safety Monitoring Board	Modest (< \$5,000)	Congenital Heart Disease and Pediatric Cardiology
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Biocardia	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol Myers Squibb	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Chiesi	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Daxor	Stock	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Daxor	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Freeline	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
HeartBeam	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Innolife	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Myokardia	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
NS Pharma	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Nuwellis	Stock	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Nuwellis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Protalix	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sangamo	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sanofi Genzyme	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Sanofi Genzyme	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Stealth Biotherapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Tenaya	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
V Wave	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Veru	Research/Research Grants	Significant (>= \$5,000)	Other
Yendii	Ownership Interest/Partnership/Principal	None (\$0)	Other

### Additional Personal Commercial Disclosures for Education Activities (0)

**Personal Organizational or Other Non-Commercial (0)**

No disclosures on record

**Clinical Trial Enroller (0)**

No disclosures on record

**Institutional Financial Decision-Making Role (0)**

No disclosures on record

**Expert Witness Testimony (1)**

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2025	Fabry disease	Plaintiff † none		Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

**Agreement****Certified Education Attestation** | Signed on 12/23/2025*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>***Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/23/2025*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>***Embargo** | Signed on 12/23/2025*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>***On-Going Obligation Agreement** | Signed on 12/23/2025**ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.